Biogen
Clinical trials sponsored by Biogen, explained in plain language.
-
Can BIIB122 slow Parkinson's? new trial results are in
Disease control CompletedThis study tested a drug called BIIB122 in 650 people with early-stage Parkinson's disease. The goal was to see if the drug could slow down the worsening of symptoms like movement problems and daily living tasks. Participants took either BIIB122 or a placebo daily for up to 3 yea…
Phase: PHASE2 • Sponsor: Biogen • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Oral MS drug shows promise for kids in landmark trial
Disease control CompletedThis completed Phase 3 trial tested the oral drug dimethyl fumarate (Tecfidera) against an injected interferon in 156 children aged 10 to 17 with relapsing-remitting multiple sclerosis. The main goal was to see if the drug could prevent new brain lesions and control the disease s…
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New MS drug combo shows promise in early trial
Disease control CompletedThis study tested an experimental drug called BIIB091, alone or combined with an approved MS drug (diroximel fumarate), in 127 people with relapsing multiple sclerosis. The goal was to check safety and see if it reduces brain inflammation on MRI scans. Participants took pills twi…
Phase: PHASE2 • Sponsor: Biogen • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New drug shows promise for rare movement disorder
Disease control CompletedThis study tested a drug called RTA 408 (omaveloxolone) in 172 people with Friedreich's ataxia, a rare genetic disease that affects movement and coordination. The goal was to see if the drug is safe and can improve exercise ability and daily function. Participants took the drug o…
Phase: PHASE2 • Sponsor: Biogen • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New MS drug shows promise for asian patients in safety trial
Disease control CompletedThis phase 3 study tested the safety and tolerability of diroximel fumarate (Vumerity) in 136 East Asian adults with relapsing forms of multiple sclerosis. Participants took the drug for up to 48 weeks, and researchers monitored side effects, lab results, and drug levels in the b…
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Spinal injection drug shows promise in stopping SMA before symptoms start
Disease control CompletedThis study tested a drug called nusinersen (Spinraza) in 25 infants who have a genetic diagnosis of spinal muscular atrophy (SMA) but no symptoms yet. The drug is given through a spinal injection to help delay or prevent the need for breathing support or early death. The goal was…
Phase: PHASE2 • Sponsor: Biogen • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Can a second treatment boost motor skills in SMA kids after gene therapy?
Disease control CompletedThis study tested the drug nusinersen (Spinraza) in 46 children under 3 years old with spinal muscular atrophy (SMA) who had previously received gene therapy but still had health challenges. The goal was to see if adding nusinersen could improve their muscle and movement abilitie…
Phase: PHASE4 • Sponsor: Biogen • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Needle-Free drug delivery tested in healthy volunteers
Knowledge-focused CompletedThis completed Phase 1 study tested whether giving the drug litifilimab under the skin using an autoinjector or a wearable on-body injector works as well as using a traditional syringe. 404 healthy volunteers received the drug by one of the three devices. Researchers measured dru…
Phase: PHASE1 • Sponsor: Biogen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
New dissolvable tablet could make taking medication easier
Knowledge-focused CompletedThis study tested whether a tablet that dissolves in liquid works the same as the capsule form of the drug omaveloxolone (SKYCLARYS). The drug is already approved for Friedreich's ataxia, but some people have trouble swallowing capsules. Seventy healthy adults took both forms in …
Phase: PHASE1 • Sponsor: Biogen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Alzheimer's drug candidate tracked in healthy brains
Knowledge-focused CompletedThis study tested a small, radioactive dose of BIIB080, an experimental Alzheimer's drug, in 5 healthy adults to see how it spreads in the brain and spinal cord. Researchers used PET scans to track the drug after a single injection into the spinal fluid. The main goal was to unde…
Phase: PHASE1 • Sponsor: Biogen • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Healthy volunteers help uncover drug interactions for FA treatment
Knowledge-focused CompletedThis completed Phase 1 study in 22 healthy volunteers looked at whether omaveloxolone (a drug for Friedreich's ataxia) changes how the body processes omeprazole (a common stomach acid reducer). Participants took omeprazole alone and then together with omaveloxolone over 17 days. …
Phase: PHASE1 • Sponsor: Biogen • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC
-
Healthy men test new version of arthritis drug
Knowledge-focused CompletedThis study tested a new drug called BIIB800 against an approved drug, Actemra, in 300 healthy men. The goal was to see if the two drugs behave similarly in the body and are equally safe. Participants received a single injection and were monitored for side effects and drug levels.
Phase: PHASE1 • Sponsor: Biogen • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC
-
Yogurt or capsule? study tests new way to take FA drug
Knowledge-focused CompletedThis study looked at how the body processes the drug omaveloxolone (SKYCLARYS®) when taken as a whole capsule versus when the capsule contents are sprinkled over low-fat yogurt. 52 healthy adults took the drug both ways to see if the body absorbs it differently. The goal is to of…
Phase: PHASE1 • Sponsor: Biogen • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC